Image Analysis Group (IAG), a leading global expert in clinical trial imaging and AI-driven biomarkers, is bolstering its presence in the United States with the launch of a new office in Cambridge, Massachusetts. This strategic move is aimed at bringing IAG’s operations and business development teams closer to the biotechnology and pharmaceutical companies concentrated in the Boston area, thereby enhancing partnerships and providing localized support for clinical trials throughout the region.
The new office is a significant development for IAG, which is involved in various therapeutic areas such as oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic diseases. The Cambridge location will facilitate closer collaboration with sponsors and contract research organizations engaged in Phase I–III clinical trials and imaging-intensive development programs. Additionally, IAG plans to generate local employment opportunities by hiring in fields such as clinical imaging operations, data science, regulatory support, and business development over the next 12 to 24 months.
This expansion underpins IAG’s comprehensive imaging services, which include clinical trial design consultation, imaging protocol optimization, centralized image analysis, and regulatory-compliant data delivery. The company aims to leverage its new position within the Boston life-sciences ecosystem to improve collaboration with biotechnology firms, pharmaceutical organizations, academic institutions, and clinical research centers.
Globally, IAG is active in supporting clinical trials across North America, Europe, and the Asia-Pacific region. It collaborates with pharmaceutical, biotechnology, and medtech companies, as well as contract research organizations (CROs), on multi-center studies. With a focus on providing standardized imaging protocols, centralized data harmonization, and consistent imaging analysis, IAG’s global operations are designed to ensure uniformity across international trials.
Founded in 2007 and headquartered in London, IAG operates as an imaging Clinical Research Organization (iCRO), assisting pharmaceutical, biotechnology, and medical technology companies with imaging-based clinical trial endpoints. The company employs its DYNAMIKA™ platform, which integrates AI-powered image analysis, centralized quality control, regulatory-compliant reporting, and real-time clinical trial oversight to drive its work across oncology, inflammatory disease, musculoskeletal, cardiometabolic, and rare disease indications.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.
